KDR and neoplasm: To hinder tumour angiogenesis, anlotinib acts on various pathways involving Vascular endothelial growth factor (VEGFR) 1, VEGFR3, VEGFR2/kinase insert domain receptor (KDR), platelet‐derived growth factor receptor‐a (PDGFR‐a), c‐Kit or fibroblast growth factor receptor (FGFR).